In a report released today, Timothy Ramey from Pivotal Research maintained a Buy rating on Nu Skin (NUS), with a price target of $85. The company’s shares closed yesterday at $69.50.
Ramey observed:
“We do expect share repurchase to accelerate and contribute meaningfully to 2019 and 2020. In 2018 diluted shares rose 2.3% compared to -2% in 2017; and -4.9% in 2016. NUS loves to shrink its share count. We think 2019 might be bigger than usual which is not in the guidance. We find the multi-year prospects for NUS shares to be excellent. Top line growth and expanding EBIT margins, accelerating share repurchases and a tax rate that may drift lower sets the stage for double-digit gains in EPS for many years. Management is excellent and improving the speed to market and technology of the business. It really is a near-perfect setup.”
According to TipRanks.com, Ramey is a 5-star analyst with an average return of 10.1% and a 61.4% success rate. Ramey covers the Consumer Goods sector, focusing on stocks such as Constellation Brands Inc, Post Holdings Inc, and Brown-Forman B.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nu Skin with a $88 average price target.
See today’s analyst top recommended stocks >>
Based on Nu Skin’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $53.15 million. In comparison, last year the company had a net profit of $18.24 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nu Skin Enterprises, Inc. engages in the development and distribution of beauty and wellness products and solutions. It operates through the following geographical segments: Mainland China, Hong Kong and Taiwan, South Korea, Japan, South Asia and Pacific, Americas, and EMEA (Europe, the Middle East, and Africa.
